Isis Reports Phase II Data Showing Antisense Rx Cuts Cholesterol Regardless of Statin Use

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

Isis Reports Phase II Data Showing Antisense Rx Cuts Cholesterol Regardless of Statin Use
By Doug Macron
November 16, 2006
RNAi News
Shares of Isis climbed more than 20 percent after data showed its antisense drug cut cholesterol levels between 50 and 60 percent alone or in combination with statin therapy.
Paid subscription is required to view article.